Rivastigmine and Tolterodine Interaction

Understanding the Rivastigmine and Tolterodine Interaction

FDA-approved prescribing information for these two drugs flags their combination as a minor-severity interaction. Rivastigmine belongs to the Acetylcholinesterase Inhibitor class and Tolterodine belongs to the Anticholinergic (Overactive Bladder) class - two categories that can collide when co-prescribed. The mechanism described in FDA labeling is: Rivastigmine works against drugs like tolterodine. Severity tiers matter: major flags generally advise avoidance, moderate flags often require monitoring or dose adjustment, and minor flags may only call for awareness.

Context around a specific patient determines real-world impact. Rivastigmine has 4 total documented interactions on file in this dataset, and Tolterodine has 15. Each additional medication compounds the interaction surface, which is why pharmacists run full-profile checks rather than evaluating one pair at a time. FDA-derived guidance for this pair is: Your healthcare provider should monitor how well your medications are working and adjust them if needed. Timing of doses, renal and hepatic function, age, and other concurrent prescriptions all shape whether a labeled interaction matters clinically.

An interaction flag is not a verdict. A large share of labeled interactions are managed routinely in clinical practice, the fix may be as simple as spacing doses or adding a monitoring test. Others require the prescriber to choose a different medication entirely. This page surfaces FDA-sourced labeling and openFDA data for educational purposes only; it is not medical advice and cannot account for your full clinical picture. Never start, stop, or adjust either Rivastigmine or Tolterodine based on a web page, speak with your prescriber or pharmacist before making any change.